Search
Showing results for "8"
Research
The dual-pathway and cognitive-behavioural models of binge eating: prospective evaluation and comparisonThe aim of this study was to evaluate and compare the dual-pathway, original cognitive-behavioural, and enhanced "transdiagnostic" cognitive-behavioural...
News & Events
The Kids researcher among Top 5 Under 40Congratulations to Gail Alvares from our Autism research team who has been named as one the ABC's Top 5 Under 40 scientists in residence.
News & Events
State Immunisation Strategy ReleasedThe State Government has launched a new strategy for improving immunisation rates among WA children, to prevent outbreaks of diseases like measles & meningitis
News & Events
Telethon Weekend 2013Make sure your family is part of the action by visiting The Kids Research Institute Australia booth at the Perth Convention & Exhibition Centre.
News & Events
Major tobacco award for Aboriginal health leaderThe 2013 Dr Bob Elphick Medal for outstanding contributions to tobacco control has been awarded to Dr Juli Coffin, Associate Professor of Aboriginal Health
News & Events
DOWNLOAD - The first research report: Patterns and trends in Mortality in WA.The Advisory Council on the Prevention of Deaths of Children and Young People today officially released this report.
News & Events
Two The Kids researchers appointed Academy FellowsThe Kids Researchers Professor Susan Prescott and Professor Donna Cross have been appointed Fellows of the prestigious Australian Academy of Health and Med
Research
A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM)Individuals who receive allogeneic hematopoietic cell transplant (allo-HCT) are immunocompromised and at high risk of pneumococcal infections, especially in the months following transplant. This study evaluated the safety and immunogenicity of V114 (VAXNEUVANCE; Merck, Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA), a 15-valent pneumococcal conjugate vaccine (PCV), when given to allo-HCT recipients.